KT-253
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C33.581391%2C-111.883082%7C42.337502%2C-71.108101%7C42.367199%2C-83.085197%7C40.879956%2C-73.879973%7C35.477402%2C-97.497902%7C32.9119%2C-96.773697%7C29.707199%2C-95.396698%7C38.862856%2C-77.223717%7C38.554298%2C-121.452003%7C32.812157%2C-96.8405%7C40.764198%2C-73.956703%7C41.0574%2C-74.069603%7C40.6395%2C-74.584%7C40.809601%2C-73.293404%7C40.370701%2C-74.147301%7C40.701202%2C-73.593452%7C41.028%2C-73.733704)
Participating Centers
There are 17 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- KT-253 is a kind of treatment called an MDM2 inhibitor. KT-253 may work by inhibiting proteins that cancer cells use to bypass the immune system to grow uncontrolled.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.